184 related articles for article (PubMed ID: 36468004)
1. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
Wu X; Wang Q; Liu P; Sun L; Wang Y
Front Genet; 2022; 13():1026871. PubMed ID: 36468004
[No Abstract] [Full Text] [Related]
2. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
3. Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
Chen H; Liu Y; Yin Z; Chen H; Wang Y; Qian Y
Cell Cycle; 2023 May; 22(9):1077-1100. PubMed ID: 36757135
[TBL] [Abstract][Full Text] [Related]
4. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
Beinse G; Just PA; Le Frere Belda MA; Laurent-Puig P; Jacques S; Koual M; Garinet S; Leroy K; Delanoy N; Blons H; Gervais C; Durdux C; Chapron C; Goldwasser F; Terris B; Badoual C; Taly V; Bats AS; Borghese B; Alexandre J
Br J Cancer; 2022 Oct; 127(6):1123-1132. PubMed ID: 35752712
[TBL] [Abstract][Full Text] [Related]
7. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
Chen J; Zhu Y; Wu W; Xu Y; Yang W; Ling L; Lin Q; Jia S; Xia Y; Liu Z; Yang Y; Gong C
Oncologist; 2024 Feb; ():. PubMed ID: 38366907
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
9. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
[No Abstract] [Full Text] [Related]
10. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S; Zhao J; Nie L; Yin W; Zhang Y; Zhao F; Ni Y; Zhang X; Wang Z; Dai J; Liu Z; Chen J; Zeng Y; Wang Z; Sun G; Liang J; Zhao X; Zhu X; Tao R; Yang J; He B; Chen N; Shen P; Zeng H
BMC Med; 2022 Jul; 20(1):237. PubMed ID: 35864546
[TBL] [Abstract][Full Text] [Related]
12. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Manié E; Popova T; Battistella A; Tarabeux J; Caux-Moncoutier V; Golmard L; Smith NK; Mueller CR; Mariani O; Sigal-Zafrani B; Dubois T; Vincent-Salomon A; Houdayer C; Stoppa-Lyonnet D; Stern MH
Int J Cancer; 2016 Feb; 138(4):891-900. PubMed ID: 26317927
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel potential homologous repair deficiency-associated genes in pancreatic adenocarcinoma via WGCNA coexpression network analysis and machine learning.
Liu C; Fang J; Kang W; Yang Y; Yu C; Chen H; Zhang Y; Ouyang H
Cell Cycle; 2023 Nov; 22(21-22):2392-2408. PubMed ID: 38124367
[TBL] [Abstract][Full Text] [Related]
14. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
[TBL] [Abstract][Full Text] [Related]
15. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
[TBL] [Abstract][Full Text] [Related]
16. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
17. Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma.
Feng J; Lan Y; Liu F; Yuan Y; Ge J; Wei S; Luo H; Li J; Luo T; Bian X
NPJ Precis Oncol; 2023 Oct; 7(1):110. PubMed ID: 37907595
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
19. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
[TBL] [Abstract][Full Text] [Related]
20. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
